Rf Acquisition CORP Ii 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
NASDAQ
RF Acquisition Corp II has amended its trust agreement and articles of association to extend the deadline for its business combination to February 15, 2027, with associated monthly deposits into its trust account.
NASDAQ
RF Acquisition Corp II shareholders approved an extension to complete a business combination until August 15, 2026, following significant share redemptions.
NASDAQ
AI drug discovery pioneer Nanyang Biologics Pte. Ltd. will merge with RF Acquisition Corp II in a $1.5 billion transaction to become a Nasdaq-listed company.
NASDAQ
Tse Meng Ng resigns from the audit committee of RF Acquisition Corp II, effective immediately, but will remain on the board of directors.
NASDAQ
RF Acquisition Corp II appoints Tuan Lee Low as a Class I director and chairman of the Audit Committee, effective May 1, 2025.
NASDAQ
RF Acquisition Corp II will allow separate trading of its ordinary shares and rights, previously bundled as units, starting July 5, 2024.
NASDAQ
RF Acquisition Corp II successfully completed its initial public offering and over-allotment option, raising a total of $115.575 million.
NASDAQ
RF Acquisition Corp II successfully closed its $100 million initial public offering, outlining the terms of its rights agreement and related transactions.